anmelden
OMX Copenhagen PI
1.348,92
PKT
+4,30
PKT
+0,32
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 19.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 16.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 10.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 04.03.21 | Novo Nordisk Conviction Buy | Goldman Sachs Group Inc. | |
| 22.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 18.02.21 | Novo Nordisk Neutral | UBS AG | |
| 16.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 11.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 10.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 09.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 08.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 04.02.21 | Novo Nordisk overweight | Barclays Capital | |
| 04.02.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 03.02.21 | Novo Nordisk Outperform | Bernstein Research | |
| 03.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 03.02.21 | Novo Nordisk Neutral | UBS AG | |
| 03.02.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 26.01.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.01.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 20.01.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 20.01.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 18.01.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 18.01.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 15.01.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 15.01.21 | A.P. Moeller - Maersk A-S (B) overweight | Morgan Stanley | |
| 14.01.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 14.01.21 | A.P. Moeller - Maersk A-S (B) buy | Deutsche Bank AG |
